Holen Sie sich die Stockscreener-App
17.02
0.41%
0.05
Schlusskurs vom Vortag:
$16.97
Offen:
$17.31
24-Stunden-Volumen:
867.01K
Relative Volume:
5.52
Marktkapitalisierung:
$1.68B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.69
$17.45
1-Wochen-Bereich:
$14.62
$18.12
52-Wochen-Spanne:
$14.62
$18.12
Definium Therapeutics Inc Stock (DFTX) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Vergleichen Sie DFTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
17.02 | 1.67B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
DFTX: RBC Capital Raises Price Target for Definium Therapeutics - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital - Investing.com
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry - TipRanks
Definium launches educational campaign on LSD for mental health - Investing.com
Definium launches educational campaign on LSD for mental health By Investing.com - Investing.com Nigeria
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care - Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Update - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation After Recent Double Digit Share Price Returns - Yahoo Finance
Deinium Therapeutics (DFTX) Is Up 8.7% After Rebrand And DT120 Anxiety Pipeline UpdateWhat's Changed - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 1-Year 110% Surge? - Yahoo Finance
DFTX (Definium Therapeutics) Momentum Rank : 10 (As of Jan. 18, 2026) - GuruFocus
Assessing Mind Medicine (MindMed) (DFTX) Valuation After Rebrand To Deinium Therapeutics And Pipeline Progress - Sahm
Definium Therapeutics stock hits 52-week high at 15.3 USD By Investing.com - Investing.com Nigeria
Definium Therapeutics stock hits 52-week high at 15.3 USD - Investing.com
Five new option listings and one option delisting on January 15th - TipRanks
MNMD: DT120 targets rapid, lasting relief for anxiety and depression, with pivotal data due in 2024 - TradingView — Track All Markets
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 - Business Wire
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol "DFTX" Effective January 15, 2026 - Yahoo Finance
Mind Medicine Inc. will Change its Ticker to DFTX from MNMD - marketscreener.com
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD) - Sahm
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 5.6%Here's What Happened - MarketBeat
Definium Therapeutics Rebrands and Highlights 2026 Pipeline - TipRanks
Definium Therapeutics (MNMD) Announces Rebranding and Ticker Cha - GuruFocus
Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Sells $339,151.65 in Stock - MarketBeat
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
MindMed Announces New Employee Inducement Grant - Business Wire
MindMed Reports Q3 2025 Financial Results and Business Updates - Business Wire
MindMed to Participate in Upcoming Investor Conferences - Business Wire
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Business Wire
MindMed to Report Q3 2025 Financial Results on November 6, 2025 - Business Wire
Mind Medicine says it announces pricing of $225 million public offering at $12.25 per share - marketscreener.com
Mind Medicine Nears Pivotal Year: Strong Fundamentals Make It A Buy (NASDAQ:MNMD) - Seeking Alpha
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today - The Motley Fool
Mind Medicine stock upgraded at Oppenheimer (MNMD:NASDAQ) - Seeking Alpha
Mind Medicine Inc.(NasdaqGS: MNMD) added to Russell 3000 Value Index - marketscreener.com
MindMed to Participate in June Investor Conferences - marketscreener.com
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer - marketscreener.com
MindMed Announces New Employee Inducement Grants - marketscreener.com
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference - marketscreener.com
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - marketscreener.com
Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence - Seeking Alpha
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - marketscreener.com
MindMed Appoints Matt Wiley as Chief Commercial Officer - marketscreener.com
MindMed to Present at Leerink's Global Healthcare Conference 2025 - marketscreener.com
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - marketscreener.com
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call (MNMD) - Seeking Alpha
MindMed to Be Added to the Nasdaq Biotechnology Index - marketscreener.com
Finanzdaten der Definium Therapeutics Inc-Aktie (DFTX)
Es liegen keine Finanzdaten für Definium Therapeutics Inc (DFTX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):